Lilly Profit Tops Estimates on Sales of Diabetes Drug

Eli Lilly & Co. (LLY), the drugmaker experiencing a wave of sales losses as patents expire, reported profit that beat analyst estimates with better-than-expected revenue from its diabetes drug Humalog.

Second-quarter net income fell 39 percent to $734 million, or 68 cents a share, from $1.21 billion, or $1.11 a year earlier, the Indianapolis-based company said today in a statement. Earnings beat by 3 cents the average of 15 analyst estimates compiled by Bloomberg.

Although total revenue declined 17 percent to $4.9 billion, Humalog sales jumped 11 percent to $700.1 million, compared with analyst estimates of $682.7 million. Sales for the antidepressant Cymbalta were $401.3 million in the quarter, beating estimates of $388.5 million.

Lilly said revenue from its animal-health business was $601 million, an 11 percent increase from the previous year. Lilly bought Novartis AG’s animal-health unit on April 22, making it the second-largest animal-health company by sales.

While the pharmaceutical sector has seen increased acquisition activity, including AbbVie Inc. (ABBV)’s $55 billion purchase of Shire Plc, Lilly isn’t interested in large-scale deals, Chief Financial Officer Derica Rice said today in a conference call with investors.

“We just have not seen the long-term benefits from those types of transactions,” Rice said. “As it relates to inversion, if that ever did come about, it would be a secondary benefit, not the primary driver of us taking any type of M&A action.”

In December, Lilly lost exclusive marketing rights for the antidepressant Cymbalta, which had $5.08 billion in 2013 sales and is projected to sell $1.51 billion this year. Lilly’s osteoporosis drug Evista lost patent protection in March.

Shares rose less than 1 percent to $64.37 at the close in New York. The drugmaker has gained 22 percent in the past 12 months.

To contact the reporter on this story: Caroline Chen in New York at

To contact the editors responsible for this story: Reg Gale at Angela Zimm, Andrew Pollack

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.